Valerie Cosson

Featured in: Favicon

Articles

Pharmacokinetic characterization and exposure-response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuria - Cosson - British Journal of Clinical Pharmacology - Wiley Online Libr

Jan 21, 2025 | bpspubs.onlinelibrary.wiley.com | Valerie Cosson |Rong Fu |Austin G. Kulasekararaj |Jun-Ichi Nishimura

What is already known about this subject Crovalimab is a novel C5 inhibitor for the treatment of paroxysmal nocturnal haemoglobinuria and in development for the treatment of other complement-mediated diseases. Crovalimab is a next-generation antibody that enables rapid and sustained C5 inhibition with subcutaneous, low-volume administration every 4 weeks in or outside of a healthcare setting, often with the option for self-administration.

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.